- In November 2022, Johnson & Johnson, a US-based leader in medical devices, pharmaceuticals, and consumer goods, acquired Abiomed for USD 16.6 billion. This acquisition strengthens Johnson & Johnson MedTech’s (JJMT) position in the cardiovascular market, focusing on advancing care for heart failure and recovery, a significant unmet healthcare need. Abiomed, a US-based company specializing in temporary external and implantable mechanical circulatory support devices, complements JJMT's portfolio, enhancing their cardiovascular offerings
